Related Experiment Video
Updated: May 12, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
[Hypertrophic cardiomyopathy in 2013]
1Centre de cardiologie non invasive, Hôpital de la Tour, Avenue J.-D. Maillard Ibis, 1217 Meyrin. georgios.giannakopoulos@latour.ch
Insights
Hypertrophic cardiomyopathy, a genetic heart condition, presents varied symptoms and outcomes. Identifying high-risk patients for preventative treatment remains a complex challenge.
Area of Science:
- Cardiology
- Genetics
- Molecular Biology
Context:
- Hypertrophic cardiomyopathy (HCM) is the most prevalent genetic heart disease.
- It stems from mutations in genes responsible for sarcomeric proteins.
- HCM exhibits diverse clinical presentations and disease progression.
Purpose:
- To summarize the complexities of hypertrophic cardiomyopathy.
- To highlight challenges in risk stratification and treatment.
Summary:
- HCM's genetic basis involves sarcomeric protein mutations, leading to heterogeneous clinical courses.
- Sudden cardiac death is a rare but unpredictable complication, especially in young individuals.
- Identifying patients for primary prevention with implantable cardioverter-defibrillators is challenging.
Impact:
- Improved understanding of HCM genetics and clinical heterogeneity.
- Potential for enhanced risk stratification strategies.
- Informs therapeutic decisions for symptomatic obstruction, including myectomy and ablation.
Abstract:
Hypertrophic cardiomyopathy is the most common genetic heart disease. It is caused by a variety of mutations in genes encoding sarcomeric proteins. Clinical presentation is heterogeneous just as the clinical course, ranging from asymptomatic forms to sudden cardiac death in the young. The latter is an unpredictable, fortunately rather uncommon, complication with no reliable preventive treatment. The complexity lies in the identification of high risk patients who could benefit from an implantable cardioverter-defibrillator in primary prevention. Symptomatic patients presenting left ventricular outflow tract obstruction despite optimal medical treatment may undergo surgical septal myectomy or percutaneous alcohol septal ablation.
Related Concept Videos
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy IV: Restrictive Cardiomyopathy
Heart Failure II: Pathophysiology
